Lincoln Pharmaceuticals Share Price

We enclosed herewith the copies of newspaper intimation with respect to the unaudited (standalone & Consolidated) Financial Results of the Company for the Quarter Ended 30 June, 2026.

• BSE India
• 1 day 5 hours ago

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Lincoln Pharmaceuticals announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c1940132427=""><strong>Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Revenue from Operations: For Q1FY27, revenue from operations stood at Rs 17,728.21 lakh, compared to Rs 18,727.73 lakh in Q4FY26, showing a QoQ decrease of 5.34%. On a YoY basis, it increased by 15.07% from Rs 15,406.67 lakh in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Other Income: The company reported other income of Rs 2,426.46 lakh in Q1FY27, up significantly from a loss of Rs 419.53 lakh in Q4FY26. It also marked a YoY increase of 58.89% from Rs 1,527.17 lakh in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Total Income: Total income for Q1FY27 was Rs 20,154.67 lakh, representing a QoQ growth of 10.09% from Rs 18,308.20 lakh in Q4FY26 and a YoY growth of 19.02% from Rs 16,933.84 lakh in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Profit Before Tax: For the quarter Q1FY27, the company reported a profit of Rs 4,755.38 lakh, an increase of 184.71% QoQ from Rs 1,670.26 lakh in Q4FY26. It reflected a YoY growth of 34.37% from Rs 3,538.92 lakh in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Net Profit: Net profit for Q1FY27 stood at Rs 3,623.45 lakh, marking a QoQ increase of 211.44% from Rs 1,163.46 lakh in Q4FY26 and a YoY increase of 30.93% from Rs 2,767.52 lakh in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Total Comprehensive Income: The company recorded a total comprehensive income of Rs 3,665.33 lakh in Q1FY27, compared to Rs 1,324.09 lakh in Q4FY26 and Rs 2,769.81 lakh in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Earnings Per Share (EPS): Basic and diluted EPS for Q1FY27 was Rs 18.09, compared to Rs 5.81 in Q4FY26 and Rs 13.82 in Q1FY26.</li> </ul> <p _ngcontent-ng-c1940132427=""><strong>Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Total Income: Consolidated total income for Q1FY27 stood at Rs 201.55 crore, representing a YoY growth of 19.02% compared to Rs 169.34 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">EBITDA: EBITDA for Q1FY27 was reported at Rs 51.70 crore, registering a YoY growth of 32.29% from Rs 39.08 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Profit Before Tax: The group achieved a profit before tax of Rs 47.55 crore in Q1FY27, up 34.36% YoY from Rs 35.39 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Net Profit: Consolidated net profit for Q1FY27 reached Rs 36.23 crore, marking a 30.90% YoY increase from Rs 27.68 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Earnings Per Share (EPS): Consolidated EPS for Q1FY27 stood at Rs 18.09 per share, compared to Rs 13.82 in Q1FY26.</li> </ul> <p _ngcontent-ng-c1940132427=""><strong>Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Revenue Growth Targets:</strong> The company is targeting Rs 1,000 crore revenue over the next three years, aiming for an annual growth rate of 15-18%. This growth is expected to be driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Export Expansion:</strong> The company currently exports to 60+ countries and plans to expand its presence to 90 countries over the next 2-3 years, supported by approvals from EU GMP and TGA Australia.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Product Portfolio:</strong> Developed 600+ formulations across 15 therapeutic areas, with more than 1,700 registered products and another 700 products under development.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Debt Status:</strong> The company remains net-debt free.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Shareholding:</strong> Foreign Institutional Investors (FII) holding in the company as on June 30, 2026, stood at 4.60%.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Credit Ratings:</strong> Crisil Ratings has reaffirmed its 'Crisil A/Stable/Crisil A1' ratings on the bank facilities of the company.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Dividend Recommendation:</strong> For <strong _ngcontent-ng-c1940132427="">FY26</strong>, the company recommended a dividend of 18%, which is Rs 1.80 per share on the face value of Rs 10 per share.</li> </ul> <p><strong _ngcontent-ng-c1940132427="">Munjal Patel, Director, Lincoln Pharmaceuticals, said:</strong> "We have started FY27 with a clear focus on building on our existing growth momentum while strengthening the core areas of our business. We are also evaluating opportunities to expand our reach across domestic territories and international markets, supported by our manufacturing capabilities and product pipeline. With our continued focus on operational efficiency, portfolio expansion and disciplined execution, we remain committed to achieving our medium-term objective of crossing Rs 1,000 crore in revenue and delivering sustainable growth for our stakeholders while maintaining a debt-free balance sheet."</p> <p><a class="lb" href="/get-document/post/pdf/5786623/" target="_blank">Result PDF</a></p>

• Trendlyne
• 2 days 4 hours ago

Un-Audited Financial Results For Quarter Ended on 30 June, 2026.

• BSE India
• 2 days 5 hours ago